Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
Recio F, Scalise CB, Loar P, Lumish M, Berman T, Peddada A, Kalashnikova E, Rivero-Hinojosa S, Beisch T, Nicosia B, Farmer T, Dutta P, Malhotra M, ElNaggar AC, Liu MC, Vaccarello L, Holloway RW.
Recio F, et al.
Gynecol Oncol. 2024 Mar;182:63-69. doi: 10.1016/j.ygyno.2023.12.025. Epub 2024 Jan 22.
Gynecol Oncol. 2024.
PMID: 38262240
Free article.
Most ctDNA-positive patients had high-risk histologies or sarcoma, versus low-risk and high-intermediate risk (H-IR) EC. Furthermore, patients with high-risk histologies who were ctDNA-positive showed shorter RFS compared to those who tested negative (HR = 9.5; p = 0.007), …
Most ctDNA-positive patients had high-risk histologies or sarcoma, versus low-risk and high-intermediate risk (H-IR) EC. Furthermore, …